These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 30055889

  • 1. Secondary carbamate linker can facilitate the sustained release of dopamine from brain-targeted prodrug.
    Thiele NA, Kärkkäinen J, Sloan KB, Rautio J, Huttunen KM.
    Bioorg Med Chem Lett; 2018 Sep 15; 28(17):2856-2860. PubMed ID: 30055889
    [Abstract] [Full Text] [Related]

  • 2. Design, synthesis and brain uptake of LAT1-targeted amino acid prodrugs of dopamine.
    Peura L, Malmioja K, Huttunen K, Leppänen J, Hämäläinen M, Forsberg MM, Gynther M, Rautio J, Laine K.
    Pharm Res; 2013 Oct 15; 30(10):2523-37. PubMed ID: 24137801
    [Abstract] [Full Text] [Related]

  • 3. The Effects of Prodrug Size and a Carbonyl Linker on l-Type Amino Acid Transporter 1-Targeted Cellular and Brain Uptake.
    Venteicher B, Merklin K, Ngo HX, Chien HC, Hutchinson K, Campbell J, Way H, Griffith J, Alvarado C, Chandra S, Hill E, Schlessinger A, Thomas AA.
    ChemMedChem; 2021 Mar 03; 16(5):869-880. PubMed ID: 33230949
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Large Amino Acid Transporter 1 Selective Liposomes of l-DOPA Functionalized Amphiphile for Combating Glioblastoma.
    Bhunia S, Vangala V, Bhattacharya D, Ravuri HG, Kuncha M, Chakravarty S, Sistla R, Chaudhuri A.
    Mol Pharm; 2017 Nov 06; 14(11):3834-3847. PubMed ID: 28958145
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The Design and Evaluation of an l-Dopa-Lazabemide Prodrug for the Treatment of Parkinson's Disease.
    Hoon M, Petzer JP, Viljoen F, Petzer A.
    Molecules; 2017 Nov 27; 22(12):. PubMed ID: 29186917
    [Abstract] [Full Text] [Related]

  • 8. Development of Sesamol Carbamate-L-Phenylalanine Prodrug Targeting L-Type Amino Acid Transporter1 (LAT1) as a Potential Antiproliferative Agent against Melanoma.
    Srisongkram T, Bahrami K, Järvinen J, Timonen J, Rautio J, Weerapreeyakul N.
    Int J Mol Sci; 2022 Jul 30; 23(15):. PubMed ID: 35955600
    [Abstract] [Full Text] [Related]

  • 9. L-Type amino acid transporter 1 (LAT1)-utilizing prodrugs are carrier-selective despite having low affinity for organic anion transporting polypeptides (OATPs).
    Huttunen J, Gynther M, Vellonen KS, Huttunen KM.
    Int J Pharm; 2019 Nov 25; 571():118714. PubMed ID: 31610281
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Quantitative insight into the design of compounds recognized by the L-type amino acid transporter 1 (LAT1).
    Ylikangas H, Malmioja K, Peura L, Gynther M, Nwachukwu EO, Leppänen J, Laine K, Rautio J, Lahtela-Kakkonen M, Huttunen KM, Poso A.
    ChemMedChem; 2014 Dec 25; 9(12):2699-707. PubMed ID: 25205473
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Over-expression of renal LAT1 and LAT2 and enhanced L-DOPA uptake in SHR immortalized renal proximal tubular cells.
    Pinho MJ, Serrão MP, Gomes P, Hopfer U, Jose PA, Soares-da-Silva P.
    Kidney Int; 2004 Jul 25; 66(1):216-26. PubMed ID: 15200428
    [Abstract] [Full Text] [Related]

  • 16. L-Type amino acid transporter 1 (lat1)-mediated targeted delivery of perforin inhibitors.
    Huttunen KM, Huttunen J, Aufderhaar I, Gynther M, Denny WA, Spicer JA.
    Int J Pharm; 2016 Feb 10; 498(1-2):205-16. PubMed ID: 26705152
    [Abstract] [Full Text] [Related]

  • 17. L-Type Amino Acid Transporter 1 (LAT1/Lat1)-Utilizing Prodrugs Can Improve the Delivery of Drugs into Neurons, Astrocytes and Microglia.
    Huttunen J, Peltokangas S, Gynther M, Natunen T, Hiltunen M, Auriola S, Ruponen M, Vellonen KS, Huttunen KM.
    Sci Rep; 2019 Sep 06; 9(1):12860. PubMed ID: 31492955
    [Abstract] [Full Text] [Related]

  • 18. Structure-activity relationship study of compounds binding to large amino acid transporter 1 (LAT1) based on pharmacophore modeling and in situ rat brain perfusion.
    Ylikangas H, Peura L, Malmioja K, Leppänen J, Laine K, Poso A, Lahtela-Kakkonen M, Rautio J.
    Eur J Pharm Sci; 2013 Feb 14; 48(3):523-31. PubMed ID: 23228412
    [Abstract] [Full Text] [Related]

  • 19. Brain uptake of ketoprofen-lysine prodrug in rats.
    Gynther M, Jalkanen A, Lehtonen M, Forsberg M, Laine K, Ropponen J, Leppänen J, Knuuti J, Rautio J.
    Int J Pharm; 2010 Oct 31; 399(1-2):121-8. PubMed ID: 20727958
    [Abstract] [Full Text] [Related]

  • 20. L-Type Amino Acid Transporter 1 Enables the Efficient Brain Delivery of Small-Sized Prodrug across the Blood-Brain Barrier and into Human and Mouse Brain Parenchymal Cells.
    Montaser AB, Järvinen J, Löffler S, Huttunen J, Auriola S, Lehtonen M, Jalkanen A, Huttunen KM.
    ACS Chem Neurosci; 2020 Dec 16; 11(24):4301-4315. PubMed ID: 33228353
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.